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ABSTRACT 
 
Extended release formulations are usually designed to reduce dose frequency and maintain 
relatively constant or flat plasma drug concentration. They minimize the adverse effects, and the 
dosing flexibility and consistency of plasma concentrations may simplify the management of 
antiepileptic drug therapy and improve the patient compliance. Active pharmaceutical ingredient 
and all other raw materials and formulated granules were performed. Preformulation studies such 
as incompatibility studies, solubility, Loss on drying, bulk density, tapped density, Carr’s index, 
Hausner’s ratio and angle of repose which really helped to formulate Extended release tablets. 
Extended release tablets of anticonvulsant drug prepared by wet granulation technique 
employing hydrophilic polymers (hydroxylpropyl methylcellulose); film coating was performed 
with instacoat yellow (hypromellose, PEG, talc, titanium dioxide, yellow iron oxide). The 
extended release behaviour of the fabricated tablets was investigated such as uniformity weight, 
hardness, friability, drug content, in-vitro dissolution study and kinetic data analysis. The 
obtained results clearly indicated that the formulated tablets results are within the range and 
when compared with all formulations, F5 sufficiently extended for 12 hrs and the release of drug 
was matrix diffusion controlled. The results of dissolution studies indicates that formulation F5 
was found to be most successful. 
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1. INTRODUCTION 
      The ideal dosage regimen is that by which an acceptable therapeutic 
concentration of drug at the site(s) of action is attained immediately and is then 
maintained constant for the desired duration of the treatment.  If the provided dose size 
and frequency of administration are correct, therapeutic steady state plasma 
concentration of a drug can be achieved promptly and maintained by the respective 
administration of conventional peroral dosage forms.  However there are number of 
potential limitations associated with this.  These limitations are:  
 The concentration of drug in the plasma and hence at the site(s) of action of the 
drug fluctuates over successive dosing intervals, even when the so-called ‘Steady-
state condition’ is achieved.  Hence it is not possible to maintain a therapeutic 
concentration of drug which remains constant at the site(s) of action for the 
duration of treatment. 
 The inevitable fluctuations of steady-state concentrations of drug in the plasma 
and hence at the site(s) of action can lead to a patient being over or under 
medicated. 
 For drugs with short biological half-lives frequent doses are required to maintain 
steady state plasma concentrations within the therapeutic range.  For such drugs, 
the maintenance of therapeutic plasma concentrations is particularly susceptible to 
the consequence of forgotten doses and the overnight no-dose period. 
 Lack of patient compliance, which is more likely in the case of regimens requiring 
frequent administration of conventional dosage forms. 
        These limitations and requirements led pharmaceutical scientists to consider 
presenting therapeutically active molecules in ‘extended release’ preparations. 
        Over the years, there has been an enormous amount of work put into 
designing drug delivery systems that can eliminate or reduce the cyclical plasma 
concentrations seen after conventional drug delivery systems are administered to 
a specified dosage regimen. 
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A variety of terms were used to describe these systems.  
 Delayed release products 
      Delayed release indicates that the drug is not being released immediately following 
administration but at a later time. 
E.g., Enteric coated tablets, Pulsatile-release capsules. 
 Repeat action products 
             Repeat action indicates that an individual dose is release fairly soon after 
administration and second or third doses are subsequently released at intermittent 
intervals. 
 Prolonged release products  
    Prolonged release indicates that the drug is provided for absorption over a longer 
period of time than from a conventional dosage form.  However there is an implication 
that onset is delayed because of an overall slower release rate from the dosage form. 
 Sustained release products 
     Sustained release indicates an  initial release of drug sufficient to provide a 
therapeutic dose soon after administration and then a gradual release over an extended 
period. 
Extended release products (ER) 
 Extended release dosage forms release drug slowly, so that plasma 
concentrations are maintained at a therapeutic level for a prolonged period of time 
(usually between 8 and 12 hours). 
Controlled release (CR) 
 Controlled release dosage forms release drug at a constant rate and provide 
plasma concentrations that remain invariant with time. 
Modified release products 
 Modified release dosage forms are defined by the USP  in those whose drug 
release characteristics of time course and/or location are chosen to accomplish 
therapeutic or convenience objectives not offered by conventional dosage forms. 
 It is interesting to note that the USP considers that the terms controlled release, 
prolonged release and sustained release are interchangeable with extended release. 
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   Extended release dosage form allows a twofold reduction in dosing frequency or 
increase in patient compliance or therapeutic performance. 
The development of the oral controlled release system has been a challenge to 
formulation scientists due to their inability to restrain and localize the system at targeted 
areas of the gastrointestinal tract.  Matrix type drug delivery systems as carriers for the 
active ingredients are interesting and promising option in developing an oral controlled 
release system. 
SUSTAINED RELEASE DOSAGE FORMS 
Conventional drug products like tablets and capsules are formulated to release the 
active drug immediately to obtain rapid and complete systemic absorption of the drug. 
The conventional dosage form maintains the constant plasma drug concentration for the 
long period of time by administering in a particular dose and at particular frequency. The 
frequency of administration or the dosing interval of any drug depends upon its half-life 
or mean residence time (MRT) and its therapeutic index. In most cases, the dosing 
interval is much shorter than the half-life of the drug resulting in a number of limitations. 
These limitations can overcome by formulating into Modified-Release dosage forms. 
Modified-release products provide either delayed-release or extended-release of the drug.
 
The terms sustained release, prolonged release or extended release are used to 
identify drug delivery systems that are designed to achieve a prolonged therapeutic blood 
or tissue levels of the drug by continuous releasing of the medication for an extended 
period of time after administration of a single dose. 
The basic rationale for controlled drug delivery is to alter the pharmacokinetics 
and pharmacodynamics of pharmacologically active moieties by using novel drug 
delivery systems and to promote therapeutic benefits while at the same time minimizing 
toxic effect. Extended release tablets and capsules are commonly taken only once or 
twice daily. Typically extended-release products provide an immediate release of drug 
which promptly produces the desired therapeutic effect which then is followed by 
gradual and continual release of additional amounts of drug to maintain this effect over a 
predetermined period of time. The sustained plasma drug levels provided by extended-
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release drug products often eliminates the need for night dosing, which provides benefit 
to the patient.
 
Advantages of Extended-Release System 
 Reduction in drug blood level fluctuations 
 Frequency reduction in dosing 
 Enhanced patient convenience and compliance 
 Reduction in adverse side effects 
 Reduction in overall health care costs 
Disadvantages 
 Loss of flexibility in adjusting the drug dose and/or dosage regimen. 
 Increased risk of sudden and total drug release or dose dumping due to failure of 
technology of the dosage unit. 
 
Drug candidates suited for extended release dosage forms 
     The drug and the therapeutic indication must be considered jointly in determining 
whether or not to develop an extended release dosage form. 
      For a successful extended release product, drug must be released from the        
dosage form at a predetermined rate, dissolve in the gastrointestinal fluids, maintain 
sufficient gastrointestinal residence time and be absorbed at a rate that will replace the 
amount of drug being metabolized and excreted. 
 Drugs having short-biological half lives 
 Drugs with fairly rapid rate of absorption and excretion 
 Drugs which are uniformly absorbed in gastrointestinal tract. 
 Drugs which require relatively smaller dosage for therapeutic effect. 
 Drugs which are used for chronic rather than acute condition. 
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 Drugs which are having good margin of safety.  The most widely used measure of 
the margin of a drug’s safety is its therapeutic index.  The larger the therapeutic 
index, the safer the drug. 
Rationale for extended release dosage forms
 
 Many drugs are not inherently long lasting and require multiple daily dosing to 
achieve the desired therapeutic results. 
       Multiple daily dosing often is inconvenient for patient and can result in 
missed doses, made up doses and patient non-compliance with therapeutic 
regimen.  
 Extended release tablets and capsules are commonly taken only once or twice 
daily compared with counterpart conventional forms that may need to be taken 
three or four times daily to achieve the same therapeutic effect. 
 Extended release products provide an immediate release of the drug that promptly 
produces the desired therapeutic effect, which is then followed by the gradual and 
continual release of additional amount of drug to maintain this effect over a 
predetermined period of time. 
 The sustained plasma drug levels provided by extended release drug products 
often times eliminate the need for right dosing that provides benefit not only to the 
patient but to the caregiver as well.    
Classification of extended release products 
   Extended release tablets are often classified according to the mechanism of drug 
release.  The following are the most common means used to achieve a slow, control 
release of drug from tablets. 
 Dissolution control 
 Diffusion control  
 Dissolution and diffusion control 
 Erosion control  
 Osmotic pump control & Ion exchange control 
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Dissolution controlled Release system  
Most of the products fall into two categories 
  (a)Encapsulation dissolution controlled systems 
Here the drug particles are coated or encapsulated by one of the several 
microencapsulation techniques with slowly dissolving materials like cellulose, PEGs, 
polymethacrylates, waxes, etc. The resulting pellets may be filled as such in hard gelatin 
capsules (popularly called as spansules) or compressed into tablets.  The dissolution rate 
of coat depends upon the solubility and thickness of the coating which may range from 1 
to 200 microns. 
 
(b)Matrix dissolution controlled systems 
Matrix systems are also called as monoliths since the drug is homogeneously 
dispersed throughout a rate-controlling medium.  They are very common and employ 
waxes such as beeswax, carnauba wax, hydrogenated castor oil, etc.  which control drug 
dissolution by controlling the rate of dissolution fluid penetration into the matrix by 
altering the porosity of tablet, decreasing its wettability or by itself getting dissolved at a 
slower rate.  The wax embedded drug is generally prepared by dispersing the drug in 
molten wax and congealing and granulating the same.  The drug release is often first-
order from such matrices. 
 
 
 
 
 
     Fig.1 Dissolution Controlled Release Systems 
       a) Matrix system b) Coated/Encapsulated System  
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Diffusion controlled Release systems 
           Diffusion of a drug molecule provides the movement from a zone of high 
concentration to that of low concentration.  Here, the formulator relies on the diffusion of 
the drug through an inert membrane barrier to control the release rate of a drug. The drug 
release rate is never zero-order since the diffusional path length increases with time as 
the insoluble matrix is gradually depleted of drug. 
          The two types of diffusion controlled systems. 
(a)Matrix diffusion controlled systems   
         The drug is dispersed in an insoluble matrix of rigid non-swellable 
hydrophobic materials or swellable hydrophilic substances. Materials used for rigid 
matrix are insoluble plastics such as PVC and fatty materials like stearic acid, bees wax, 
etc.  
          Swellable matrix systems are popular for sustaining the release of highly water-
soluble drugs.  The material for such matrices are generally hydrophilic gums and may 
be of natural origin (Guar gum, Tracaganth), semi synthetic (HPMC,CMC, Xanthan 
gum) or synthetic (Poly acrylamides) 
        The release of drug from such matrix systems involve simultaneous absorption of 
water (resulting in hydration, gelling and swelling of gum) and desorption of drug  
via a swelling controlled diffusion mechanism.  As the gum swells and the drug diffuses 
out of it, the swollen mass, devoid of drug appears transparent. 
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Fig.2 Diffusion Controlled Systems 
                                a) Rigid matrix b) Swellable matrix  
(b)Reservoir diffusion controlled systems 
These systems are hollow containing an inner core of drug surrounded in a water 
&insoluble polymer membrane.  The polymer can be applied by coating or 
microencapsulation techniques. The drug release mechanism across the membrane 
involves its partitioning into the membrane with subsequent release into the surrounding 
fluid by diffusion.  The polymers commonly used in such devices are HPC, Ethyl 
cellulose and polyvinyl acetate. 
A disadvantage of all such microencapsulated drug release systems is a chance of 
sudden drug dumping which is not common with matrix devices. 
 
 
 
 
 
Fig.3 Drug release by diffusion across the insoluble membrane 
Dissolution and diffusion controlled release systems 
A combined dissolution and diffusion control of drug release can be 
accomplished by coating a drug core with a partially soluble membrane.Usually this 
membrane contains a combination of hydrophobic and hydrophilic polymers. 
         Eg., a mixture of ethyl cellulose and pvp. 
The dissolution of the hydrophilic polymer causes the formation of pores through 
the membrane 
      -Permit the entry of aq. medium into the core and hence drug dissolution 
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      -Allow diffusion of dissolved drug out of the system 
 
 
 
 
 
 
Fig.4 Dissolution and Diffusion Controlled Release System 
 
            
 
  
 
 
Formulation of extended release system 
There are three main classes of delivery system 
 Monolithic or matrix systems 
 Reservoir or membrane controlled systems 
 Osmotic pump systems. 
There is a basic principle that governs all these systems.  In a solution drug diffusion 
will occur from a region of high concentration to a region of low concentration.  This 
concentration difference is the driving force of drug diffusion out of the system 
8
. 
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Components of extended release delivery system 
These include  
 Active drug 
 Release controlling agents (matrix formers, membrane formers) 
 Matrix or membrane modifier, such as channeling agents for wax matrices and 
solublisers/and wicking agents for hydrophilic matrices 
 Solubiliser, pH modifier and density modifier 
 Lubricant and flow aid 
 Density modifiers ( if any) 
 
EPILEPSY 
 
 
 Epilepsy is a neurological disorder characterized by unprovoked, recurring 
seizures that disrupt the nervous system and can cause mental and physical 
dysfunction. 
  The structures of the brain include the spinal cord, the brainstem, consisting of  
the medulla oblongata, the pons and the midbrain; the cerebellum; the cerebrum 
(one half, or hemisphere shown); and the diencephalon. 
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Fig 5: Internal structure of brain  
 
 Criteria for Classifying Epilepsies and Seizures 
 Seizures are a symptom of epilepsy. Epilepsy types are generally put into two 
categories, which are based on the specific biologic mechanisms involved in the 
seizure and the anatomical location of the seizure. The two types are: 
 Partial (also called focal or localized) seizures: These seizures are more common 
than generalized seizures and occur in one or more specific locations in the brain. 
In some cases, partial seizures can spread to wide regions of the brain. They are 
likely to develop from specific injuries, but in most cases the exact origins are 
unknown. 
 Generalized seizures:These seizures typically occur in both sides of the brain. 
Many forms of these seizures are genetically based. There is usually normal 
neurologic function. 
 New classification systems better define specific epilepsies. Some professional 
groups now suggest that epilepsies be classified in the following five ways: 
 
 Type of seizure (partial or generalized) 
 Description of the seizure onset and evolution 
 Specific syndromes that are associated with one or more seizure types (however, 
not all seizures will be part of a syndrome) 
 Specific causes of the seizures, if known 
 Degree of impairment 
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 Partial Seizures (also called Focal Seizures) 
 These seizures are subcategorized as "simple" or "complex partial." 
 Simple Partial Seizures:A person with a simple partial seizure (sometimes known 
as Jacksonian epilepsy) does not lose consciousness, but may experience 
confusion, jerking movements, tingling, or odd mental and emotional events. Such 
events may include deja vu, mild hallucinations, or extreme responses to smell and 
taste. After the seizure, the patient usually has temporary weakness in certain 
muscles. 
 Complex Partial Seizures: Slightly over half of seizures in adults are complex 
partial type. About 80% of these seizures originate in the temporal lobe, the part of 
the brain located close to the ear. Disturbances there can result in loss of 
judgment, involuntary or uncontrolled behavior, or even loss of consciousness. 
They may lose consciousness briefly and appear to others as motionless with a 
vacant stare. Emotions can be exaggerated; some sufferers even appear to be 
drunk. After a few seconds, a patient may begin to perform repetitive movements, 
such as chewing or smacking of lips. Episodes usually last no more than 2 
minutes. They may occur infrequently, or as often as every day. A throbbing 
headache may follow a complex partial seizure. 
 Generalized seizures are caused by nerve cell disturbances that occur in more 
widespread areas of the brain than do partial seizures. Therefore, they have a more 
serious effect on the patient. They are further subcategorized as tonic-clonic (or 
grand mal) or absence (petit mal) seizures. 
 Tonic-Clonic (Grand Mal) Seizures:The first stage of a grand mal seizure is 
called the tonic phase, in which the muscles suddenly contract, causing the patient 
to fall and lie stiffly for about 10 - 30 seconds. Some people experience a 
premonition or aura before a grand mal seizure. Most, however, lose 
consciousness without warning. If the throat or larynx is affected, there may be a 
high-pitched musical sound (stridor) when the patient inhales. Spasms occur for 
about 30 seconds to 1 minute. Then the seizure enters the second phase, called the 
clonic phase. The muscles begin to alternate between relaxation and rigidity. After 
this phase, the patient may lose bowel or urinary control. The seizure usually lasts 
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a total of 2 - 3 minutes, after which the patient remains unconscious for a while 
and then awakens to confusion and extreme fatigue. A severe throbbing headache 
similar to migraine may also follow the tonic-clonic phases. 
 Absence (Petit Mal) Seizures: Absence or petit mal seizures are brief losses of 
consciousness that occur for 3 - 30 seconds. Physical movement and loss of 
attention may stop for only a moment. Such seizures may pass unnoticed by 
others. Young children may simply appear to be staring or walking distractedly. 
Petit mal may be confused with simple or complex partial seizures, or even with 
attention deficit. Attention deficit hyperactivity disorder. In petit mal, however, a 
person may experience attacks as often as 50 - 100 times a day. About 25% of 
patients with petit mal develop grand mal seizures. An electroencephalogram 
(EEG) test that shows a specific brain wave pattern can usually identify these 
patients. 
 Other Seizures 
 Atonic (Akinetic) Seizures:A person who has an atonic (or akinetic) seizure loses 
muscle tone. Sometimes it may affect only one part of the body so that, for 
instance, the jaw slackens and the head drops. At other times, the whole body may 
lose muscle tone, and the person can suddenly fall. A brief atonic episode is 
known as a drop attack. 
 Simple Tonic or Clonic Seizure: Seizures can also be simply tonic or clonic. In 
tonic seizures, the muscles contract and consciousness is altered for about 10 
seconds, but the seizures do not progress to the clonic or jerking phase. Clonic 
seizures, which are very rare, occur primarily in young children, who experience 
spasms of the muscles but not tonic rigidity. 
 Myoclonic: Myoclonic seizures are a series of brief jerky contractions of specific 
muscle groups, such as the face or trunk. 
 Epileptic Syndromes:Epilepsy is also grouped according to a set of common 
characteristics, including: 
 Patient age 
 Type of seizure or seizures 
 Whether a cause is known or not (idiopathic) 
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A few syndromes and inherited epilepsies are listed as follows. 
 West Syndrome (Infantile Spasms): West syndrome, also called infantile spasms, 
is a disorder that involves spasms and developmental delay in children within the 
first year, usually in infants ages 4 - 8 months. 
 Benign Familial Neonatal Convulsions: Benign familial neonatal convulsions 
(BFNC) are a rare, inherited form of generalized seizures that occur in infancy. 
BFNC appears to be caused by genetic defects that affect ion channels in nerve 
cells that carry potassium. 
 Juvenile Myoclonic Epilepsy (Impulsive Petit Mal):Juvenile myoclonic epilepsy, 
also called impulsive petit mal epilepsy, is characterized by generalized seizures, 
usually tonic-clonic marked by jerky movements (called myoclonic jerks), and 
sometimes absence seizures. This accounts for 7% of epilepsies, and usually 
occurs in individuals ages 8 - 20. 
 Adult Myoclonic Epilepsy:Some research suggests that adult myoclonic epilepsy 
may be a previously un-described and distinct syndrome. It involves the 
development of generalized epilepsy of unknown causes in middle-aged adults. 
 Lennox-Gastaut Syndrome: Lennox-Gastaut syndrome is a severe form of 
epilepsy in young children that causes multiple seizures and some developmental 
retardation. It usually involves absence, tonic, and partial seizures. 
 Myoclonic-Astatic Epilepsy: Myoclonic-astatic epilepsy (MAE) is a combination 
of myoclonic seizures and astasia (a decrease or loss of muscular coordination), 
often resulting in the inability to sit or stand without aid. 
 Progressive Myoclonic Epilepsy: Progressive myoclonic epilepsy is an inherited 
disorder occurring in children ages 6 - 15. It usually involves tonic-clonic seizures 
and marked sensitivity to light flashes. Although the disease was previously 
considered to be progressive throughout life, current therapies have significantly 
improved its outlook. 
 Autosomal Dominant Nocturnal Frontal Lobe Epilepsy: Autosomal dominant 
nocturnal frontal lobe epilepsy (ADNFLE) is a rare, inherited syndrome that 
usually occurs during childhood, typically around age 11. However, onset varies 
widely within families. Seizures can be dystonic (twisting contractions) or tonic 
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(muscle contractions), or involve thrashing. They are brief, frequent, and occur in 
clusters during the night. The seizures often subside with age. ADNFLE appears 
to be caused by an alteration in the brain receptor neuronal nicotinic acetylcholine, 
 Landau-Kleffner Syndrome:. Landau-Kleffner syndrome is an epileptic condition 
that results in the inability to communicate either with speech or by writing 
(aphasia). 
 Contactin-Associated Protein-Like 2 (CASPR2) Epilepsy: CASPR2 is associated 
with a childhood epilepsy and autism disorder found in closely related relatives in 
Amish communities. 
 Status Epilepticus 
 Status epilepticus (SE) is a serious, potentially life-threatening, condition that can 
lead to chronic epilepsy. It occurs in 100,000 - 150,000 people in the U.S. each 
year, over half of whom are children. Permanent brain damage or death can result 
if the seizure is not treated effectively. 
 The condition is defined as recurrent convulsions that last for more than 20 
minutes and are interrupted by only brief periods of partial relief. Although any 
type of seizure can be sustained or recurrent, the most serious form of status 
epilepticus is the generalized convulsive or tonic-clonic type. In more than a third 
of cases, status epilepticus occurs with the first seizure. The trigger is often 
unknown, but can include the following: 
 Failure to take anti-epileptic medications (accounts for about a third of status 
epilepticus events) 
 Abrupt withdrawal of certain anti-epileptic drugs, particularly barbiturates and 
benzodiazepines 
 High fever, poisoning 
 Electrolyte imbalances (imbalance in calcium, sodium, and potassium) 
 Cardiac arrest, stroke 
 Low blood sugar in people with diabetes 
 Central nervous system infection 
 Brain tumor 
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CLASSIFICATON 
 
1.Barbiturate: Phenobarbitone: MOA:GABA facilitatory, GABAmimetic,  
calcium entry reduction. 
2. Deoxybarbitone: Primidone:MOA:deoxybarbiturate,converted by liver to 
phenobarbitone   and phenylethyl malonamide. 
3. Hydantoin: Phenytoin:MOA: Prolonging the inactivated state of sodium 
channel, reduction in calcium influx, inhibition of glutamate, facilititation of 
GABA. 
4. Iminostilbene: Carbamazepine 
5. Succinimide: Ethosuximide:MOA:It selectively suppresses T current without 
affecting other types of Ca
2+
 or Na
+
 currents.It also does not potentiate GABA at 
therapeutic concentrations. 
6. Aliphatic carboxylic acid: Valproic acid 
MOA: 
i. A phenytoin-like frequency-dependant prolongation of Na
+
 channel inactivation. 
ii.weak attenuation of Ca
2+
 mediated ‘t’ current (ethosuximide like). 
iii.augmentation of release of inhibitory transmitter GABA by inhibiting its 
degradation(by GABA-TRANSAMINASE) and increasing its synthesis from 
glutamic acid. 
7. Benzodiazepine:Diazepam,Clonazepam:MOA: chloride conductance(GABA 
facilitatory action).  
8. Phenyltriazine: Lamotrigine: 
MOA:prolongation of Na
+
 channel inactivation and suppression of high frequency 
firing has been demonstrated. In addition ,it may directly block voltage sensitive 
Na
+ 
 channels thus stabilizing the presynaptic membrane and preventing release of 
excitatory neurotransmitters,mainly glutamate and aspartate. 
9. Cyclic GABA analogue:Gabapentin:MOA:This lipophilic GABA derivative 
crosses to the brain and enhances GABA release, but does not act as agonist at 
GABAa receptor. 
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2. REVIEW OF LITERATURE 
 
1. Tomuţă I and Leucuţa SE  reported  the development and the in vitro evaluation of 
extended release multiparticulate dosage forms with carbamazepine, starting from 
drug crystals of established granulometry as cores and using Eudragit NE aqueous 
dispersions as coating film polymer in a bottom spray fluid bed coating system. The 
chosen independent variables, i.e., the quantity of film coating (Eudragit NE) and the 
% of hydrophilic polymer in film coating that act as pores generating (hydroxypropyl 
methylcellulose ratio) were optimized. The chosen dependent variables were 
cumulative percentage values of carbamazepine released after 1, 2, 4, 6, 8 and 12 h 
and Peppas kinetic release equation parameters (k and n). Based on the experimental 
design, different carbamazepine formulations were proposed and their release profiles 
were determined. The dissolution profile of carbamazepine from the coated crystals 
and tablets prepared with them were similar, and were unchanged after storage for 3 
months under controlled conditions. 
 
2. Cameron F et al., Vivus proprietary oral capsule containing phentermine and 
extended-release (ER) topiramate used for the treatment of obesity. Phentermine is an 
appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily 
formulation, known as Qsymia™, is designed to produce weight loss by decreasing 
appetite and increasing satiety. The product is also in clinical development for sleep 
apnoea syndrome and type 2 diabetes mellitus. 
 
3. Sylvain Rheims and Philippe Ryylin formulated and evaluated once daily 
lamotrigine extended release for epilepsy management. Once daily XR formulation 
contains a modified release eroding matix formulation designed to control the 
dissolution rate of lamotrigine. 
 
4. Amol Chaudhary developed once-daily extended release tablet of Lamotrigine, an 
Anticonvulsant. The tablets were prepared by the wet granulation method. 
Lamotrigine using hydrophilic matrix material (Methocel K4M & Methocel 
K100LV) in combination with hydrophobic material (Eudragit L-30D-55) were used, 
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which can release the drug upto 24hrs in predetermined rate. Diluents used were 
lactose monohydrate and magnesium starate as lubricant. The influence of 
hydrophilic and hydrophobic polymer and granulation technique was studied. The 
formulated tablets were also characterized by physical and chemical parameters. The 
granules showed satisfactory flow properties, compressibility, and drug content.  
 
5. Ye Huang et al., The purpose of this study was to investigate the effect of three 
process variables: distribution of hydroxypropyl methylcellulose (HPMC) within the 
tablet matrix, amount of water for granulation, and tablet hardness on drug release 
from the hydrophilic matrix tablets.Tablets were made both by direct compression as 
well as wet granulation method. 
 
6. Sandra Furlanetto and Marzia Cirri., reported the study of formulation variables 
influencing the drug release rate from matrix tablets by experimental design. 
Experimental design was utilized to simultaneously investigate the effect of varying 
the type of diluent (insoluble Calcium phosphate or water-soluble arabic gum) and 
the diluent/matrix ratio on the drug release behaviour from both lipophilic (glyceryl 
behenate, Compritolw) or hydrophilic (hydroxypropylmethylcellulose) matrix tablets. 
Ketoprofen, theophylline and sodium sulphadiazine were selected as model drugs on 
the basis of their respectively very low, medium and high water-solubility, in order to 
evaluate the influence of this parameters. 
 
7. Meir bailer et al., This review analyses the concept of extended-release (ER) 
formulations in epilepsy and evaluates ER formulations of carbamazepine, valproic 
acid and a modified-release (MR) formulation of AED. ER formulations are usually 
designed to reduce dose frequency and maintain relatively constant or flat plasma 
drug concentration. It is questionable whether flatplasmaconcentrations of an 
antiepileptic drug (AED) improve antiepileptic efficacy compared with fluctuating 
plasma concentrations. 
 
8. Eman Atef and Albert A. BelmonteEman Atef developed and characterized a self-
emulsifying drug delivery system (SEDDS) of phenytoin, and to compare its relative 
bioavailability to a commercially available suspension. Four phenytoin SEDDS were 
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prepared and evaluated. Following emulsification, the optimized formula was 
selected to have the smallest mean particle size and the highest absolute zeta 
potential, which should yield the formation of a stable emulsion. In vivo and in vitro 
tests were run to compare the optimized formula, SEDDS II, to a commercially 
available Dilantin
®
 suspension. The in vitro dissolution indicated a significant 
improvement in phenytoin release characteristics. The in vivo study using male rats 
showed a clear enhancement in phenytoin oral absorption from SEDDS compared to 
Dilantin
®
 suspension. 
 
9.  Nimmathotta Madhavi N et al., The aim of this study is to develop sustained 
release matrix tablet of phenytoin sodium using eudragit- RL100, eudragit-RS100, 
HPMC-E15, ethyl cellulose (N-14), Chitosan and HPMC as release controlling factor 
and to evaluate drug release parameters as per various release kinetic models. The 
formulated tablets were also characterized by physical and chemical parameters and 
results were found in acceptable limits. Different dissolution models were applied to 
drug release data in order to evaluate release mechanisms and kinetics. Based on “n” 
value (0.168) the drug release followed Fickian diffusion. Also the drug release 
mechanism was best explained in Higuchi order by using this polymer. 
 
10. Rompicharla Bhargavi et al., formulated, developed and evaluated gabapentin 
matrix tablets. Gabapentin is an anti epileptic drug used for the treatment of epileptic 
seizures and in treatment of post therapeutic neuralgia.  In this study controlled 
released Gabapentin matrix tablets were prepared by using different matrix forming 
polymers which include hydrophilic polymers like HPMC K15M, HPMC K100M, 
Xanthan gum and hydrophobic polymer like Ethylcellulose in various ratios to retard 
the release of drug upto 12hrs. The formulations containing the combination of 
hydrophilic and hydrophobic polymer combinations (HPMC K100M with 
Ethycellulose) and the formulations prepared with the combination of two 
hydrophilic polymers of synthetic and natural origin (HPMC K100M with Xanthan 
Gum) exhibited maximum drug release(99%) upto12hrs during in vitro dissolution 
studies with optimum swelling characteristics. 
 
11. Wael Ali et al., Formulated and evaluated Carbamazepine200 mg Controlled Release 
Tablets Using Different HPMC Grades. Possible interaction between carbamazepine 
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and different HPMC grades was done using DSC thermal analysis. Seven 
preparations of carbamazepine 200 mg controlled release tablets were prepared by 
wet granulation method and one preparation was prepared by direct compression 
method where different HPMC grades with different ratios were used.Concerning 
uniformity of weight, hardness and assay; all tablets conformed to pharmacopeial 
limits. Dissolution of the prepared tablets was done using basket method for 24 hours 
and paddle method for 4 hours. Drug release kinetics was under zero order. 
 
12. Alfred Fahr et al., reported physicochemical characterization of solid dispersions of 
three antiepileptic drugs prepared by solvent evaporation method. We have 
investigated the solid dispersion and dissolution profiles of three antiepileptic drugs 
(carbamazepine, rufinamide, and an AED) with different aqueous solubilities, 
prepared by the solvent evaporation method. Solid dispersions of the three drugs in 
hydroxy-propylmethylcellulose (HPMC), with drug:polymer ratios of 1:4, were 
prepared and characterized by differential scanning calorimetry (DSC), Fourier 
transformation infrared (FTIR) spectroscopy, X-ray diffraction (XRD) and scanning 
electron microscopy. The release mechanism was also investigated and the kinetic 
order of the solid dispersions was evaluated. Thus, solid dispersions of these drugs 
had an improved dissolution profile.  
 
13. R. Valarmathi et al., made a review on Lacosamide (LCM) and its analytical 
methods. Lacosamide, a new antiepileptic drug approved by US-FDA for the 
treatment of partial onset seizure. Lacosamide has less severe side effects and less 
drug interactions with other drugs. There are several analytical methods including 
UV, HPLC, HPTLC have been reported for determination of lacosamide in its 
pharmaceutical dosage forms. Lacosamide in human and rat plasma is determined 
using LC-MS. Stability indicating HPLC have also been reported for Lacosamide. 
 
14.  Swati Dubey et al., Simultaneous determination of three traditional and two novel 
Antiepileptic Drugs using Micellar Liquid Chromatography. This paper discussed 
about the determination of five antiepileptic drugs (carbamazipine, clobazam, 
lamotigine, phenytoin and topiramate) using C18 column (5μm, 250×4.6mm) hybrid 
mobile phases containing sodium dodecyl sulfate (SDS) as surfactant and pentanol as 
modifier. Detection was performed with a diode array detector at 230nm. 
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15.  Harshal Pawar et al., A simple, precise and reproducible reverse phase, isocratic 
high performance liquid chromatographic (HPLC) method was developed and 
validated for the quantitative determination of Valproic Acid in the dissolution study 
of Pharmacosomes. The quantification was carried out using a Zorbax Eclipse XBD- 
C18 (4.6 × 150mm, 5 μm) column, with a mobile phase consisting of Acetonitrile: 
Citric acid buffer (50:50, v/v) (pH 3) at a flow rate of 1.5 ml/min and UV detection at 
210 nm. The method was validated for specificity, method precision, linearity, 
recovery, robustness, ruggedness and solution stability. The proposed method was 
successfully applied for determination of the Valproic Acid in dissolution study of 
Pharmacosomes 
 
16. Emilio Perucca demonstrated Extended-Release Formulations of Antiepileptic 
Drugs: Rationale and Comparative Value Extended-release products are designed to 
prolong the absorption of drugs with short half-lives, thereby allowing longer dosing 
intervals while minimizing fluctuations in serum drug levels. The relationship 
between serum drug concentration and clinical effects of antiepileptic drugs (AEDs) 
can be complex and reducing fluctuations in serum drug levels is not equally 
advantageous for all AEDs. Extended-release formulations have been shown to be 
particularly valuable for carbamazepine. 
 
17. Imran Ali et al., compared the pharmacokinetics (PK) of lamotrigine (LTG) when 
converting from twice-daily immediate-release (LTG-IR) to once-daily extended-
release (LTG-XR) in subjects with epilepsy. 
 
18. J. Emami et al., A simple HPLC method was developed and validated for 
quantitation of lamotrigine and its related substances which may coexist in solid 
pharmaceutical dosage forms. The HPLC separation was achieved on a C18 μ 
column (250 mm × 4.6 mm) using a mobile phase of acetonitrile–monobasic 
potassium phosphate solution (35:65, v/v) containing orthophosphoric acid to adjust 
pH to 3.5 at a flow rate of 1.5 ml/min. The UV detector was operated at 210 nm, and 
column temperature was adjusted at 40 °C. The method was validated for specificity, 
linearity, precision, accuracy, robustness and limit of quantitation. 
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19. Abhay Gupta et al., studied the Development and application of a validated HPLC 
method for the determination of gabapentin and its major degradation impurity in 
drug products. 
 
20. Md Sajid Ali et al. developed sustained release matrix tablets of phenytoin sodium 
an antiepileptic drug. The tablets were fabricated by the wet granulation method 
using water as granulating agent along with matrix materials like guar gum, sodium 
alginate, tragacanth and xanthan gum with varying percentage. The granules were 
evaluated for angle of repose,bulk density, compressibility index, total porosity, and 
drug content. The tablets were subjected to weight variation test, drug content, 
hardness,friability, and in vitro release studies. The swelling behavior of matrix was 
also investigated. The most successful  exhibited satisfactory drug release extended 
the release up to 12 hours. The mechanism of drug release from all the formulations 
was diffusion coupled with erosion. 
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3. DRUG PROFILE 
Category: Anti-epileptic drug 
Description: 
 Yellow crystalline powder. 
Solubility: 
Soluble in acetic acid, sparingly soluble in chloroform, practically insoluble in water. 
Mechanism of action: 
The pharmacologic activity is primarily through the active metabolite of the drug, but 
the exact mechanism is unknown. It may block voltage-sensitive sodium channels, 
resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive 
neuronal firing, and diminution of propagation of synaptic impulses.  
 
Pharmacodynamics: 
 
Changing the molecular structure of the drug helps in reducing the impact on the liver  
and also prevents the serious forms of anemia occasionally associated with the drug. 
Aside from this reduction in side effects, it is thought to have the same mechanism as 
carbamazepine - sodium channel inhibition - and is generally used to treat the same 
conditions. 
 
Pharmacokinetics 
Absorption 
Completely absorbed and extensively metabolized to active metabolite. Steady-state 
concentrations of active metabolite of drug are reached in 2 to 3 days when given 
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twice daily. For tablet form, T max is 4.5 h. For oral suspension form, T max is 6 h. 
Food had no effect on the rate and extent of absorption. 
Distribution 
The apparent volume of distribution (Vd) for active metabolite is 49 L. 
Approximately 40% of active metabolite is protein bound, predominantly to albumin. 
Metabolism 
Rapidly reduced by cytosolic enzymes in the liver to active metabolite, which is 
primarily responsible for the pharmacologic effect. Active metabolite is metabolized 
further by conjugation with glucuronic acid. 4% is oxidized to inactive 10,11-
dihydroxy metabolite (DHD). 
Elimination 
Less than 1% eliminated unchanged through the kidneys. 80% excreted as 
glucuronides of active metabolite (49%) or as unchanged (27%); inactive DHD 
accounts for 3%, and conjugates of active metabolite account for 13%. 
Adverse reactions:  
The most commonly observed adverse reactions seen in association with drug were 
dizziness, somnolence, headache, balance disorder, tremor, vomiting, diplopia, 
asthenia, and fatigueness. 
Half Life: 
The half-life of the parent is about 2 hours, while the half-life of active metabolite 
about 9 hours, so that active metabolite is responsible for most anti-epileptic activity. 
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4. EXCIPIENTS PROFILE 
A. HYDROXY PROPYL METHYL CELLULOSE 
Synonyms: 
 Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; hypromellosum; 
 Methocel; methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; 
Metolose;MHPC 
 
Official Status: BP: Hypromellose 
                           JP: Hypromellose 
                           PhEur: Hypromellose 
                           USP: Hypromellose  
STRUCTURAL FORMULA: 
  
where R is H, CH3, or CH3CH(OH)CH2 
Functional Category: 
Bioadhesive material; coating agent; controlled-release agent; dispersing agent; 
dissolution enhancer; emulsifying agent; emulsion stabilizer; extended-release agent; 
film forming agent; foaming agent; granulation aid; modified-release agent; 
mucoadhesive; release modifying agent; solubilizing agent; stabilizing agent; 
suspending agent; sustained-release agent;tablet binder; thickening agent; viscosity-
increasing agent. 
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Description: 
Hypromellose is an odourless and tasteless, white or creamy-white fibrous or granular 
 powder. HPMC K 15M can successfully be used in mortars and plasters which are 
manually applied. The product imparts good workability to mortars and plasters and 
enhances water  retention. HPMC 15CPS and HPMC K 4M cellulose derivatives also 
been used as in these  formulation. Solubility Soluble in cold water, forming a viscous 
colloidal solution; practically insoluble in hot water, chloroform, ethanol (95%), and 
ether, but soluble in mixtures of ethanol and dichloromethane, mixtures of methanol 
and dichloromethane, and mixtures of water and alcohol. Certain grades of 
Hypromellose are soluble in aqueous acetone solutions, mixtures of dichloromethane 
and propan-2-ol, and other organic solvents. Some grades are swellable in ethanol. 
 
 Grades: 
 Higher viscosity grades leading to greater diffusional resistance to water. This 
directly  reduces the diffusion of drug out of the matrix and indirectly affects the state 
of hydration within  the gel, thus affecting that component of drug release due to 
erosion of the dosage form. Methocel K 4M (4000 Cps), K 15M (15000 Cps) and K 
100M (100000 Cps) were similar despite differences in viscosities. Methocel K 
100M>Methocel K 15M>Methocel K 4M based on viscosities. 
 
 Handling Precautions: 
 Observe normal precautions appropriate to the circumstances and quantity of material 
 handled. Hypromellose dust may be irritating to the eyes, so eye protection is 
recommended. Excessive dust generation should be avoided to minimize the risks of 
explosion. Hypromellose is combustible. 
 
 Storage: 
 Hydroxy Propyl Methyl Cellulose powder should be stored in a well-closed 
container, in  a cool, dry place. 
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B.LACTOSE  MONOHYDRATE 
 
Synonyms: 
 CapsuLac; GranuLac; Lactochem; lactosum monohydricum; Monohydrate; 
Pharmatose;PrismaLac; SacheLac; SorboLac; SpheroLac; SuperTab 30GR; 
Tablettose. 
 
Official Status: BP: Lactose 
                           PhEur: Lactose Monohydrate 
                           JP: Lactose Hydrate 
                           USP-NF: Lactose Monohydrate 
 
 Structural Formula:  C12H22O11.H2O 
 
Functional Category: 
 Dry powder inhaler carrier; lyophilization aid; tablet binder; tablet and capsule 
diluent; tablet and capsule filler. 
 
 Description: 
 In the solid state, lactose appears as various isomeric forms, depending on the 
 crystallization and drying conditions, i.e. lactose monohydrate, b-lactose anhydrous, 
and lactose anhydrous. The stable crystalline forms of lactose are a-lactose 
monohydrate, b-lactose anhydrous, and stable a-lactose anhydrous. Lactose occurs as 
white to off-white crystalline particles or powder. Lactose is odourless and slightly 
sweet-tasting; a-lactose is approximately  20% as sweet as sucrose, while b-lactose is 
40% as sweet. 
 
 Handling Precautions: 
 Observe normal precautions appropriate to the circumstances and quantity of material 
 handled. Excessive generation of dust, or inhalation of dust, should be avoided. 
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C.POVIDONE (PVP K-30) 
 
 Synonyms: 
 E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; 
 polyvinylpyrrolidone; povidonum; Povipharm; PVP; 1- vinyl-2-pyrrolidinone 
polymer. 
 
 Official Status: BP: Povidone 
                           JP: Povidone 
                           PhEur: Povidone 
                                USP: Povidone 
 
 Functional Category: 
 Disintegrant; dissolution enhancer; suspending agent; tablet binder. 
 
Structural Formula: 
 
  
 
 Povidone occurs as a fine, white to creamy-white coloured, odourless or almost 
odourless, hygroscopic powder. Freely soluble in acids, chloroform, ethanol (95%), 
ketones, methanol, and water, practically insoluble in ether, hydrocarbons, and 
mineral oil. In water, the concentration of  a solution is limited only by the viscosity 
of the resulting solution, which is a function of the K30 value. 
 
Handling Precautions: 
Observe normal precautions appropriate to the circumstances and quantity of material 
 handled. Eye protection, gloves, and a dust mask are recommended. 
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 Storage: 
 Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, it should be 
stored in an airtight container in a cool, dry place. 
 
D.COLLOIDAL SILICON DIOXIDE 
 
 Synonyms: 
Aerosil; Cab‐O‐Sil; colloidal silica; fumed silica; light anhydrous silicic acid; 
silicic anhydride; silicon dioxide fumed. 
 
 Official Status: BP: Colloidal Anhydrous Silica 
                           JP: Light Anhydrous Silicic Acid 
                                 PhEur: Silica, Colloidal Anhydrous 
                                 USP-NF: Colloidal Silicon Dioxide 
 
 Structural Formula: SiO2 
 
 Functional Category: 
 Adsorbent; anti caking agent; emulsion stabilizer; glidant; Suspending agent; tablet 
 disintegrant; thermal stabilizer; viscosity‐increasing agent. 
 
 Description: 
 Colloidal silicon dioxide is sub microscopic fumed silica with a particle size of about 
15 nm. It is a light, loose, bluish white‐ coloured, odourless, tasteless, non gritty 
amorphous powder. 
 
 Solubility: 
 Practically insoluble in organic solvents, water, and acids, except hydrofluoric acid; 
 soluble in hot solutions of alkali hydroxide. Forms a colloidal dispersion with water. 
 
 Handling Precautions: 
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 Eye protection and gloves are recommended. Precautions should be taken to avoid 
 inhalation of colloidal silicon dioxide. In the absence of suitable containment 
facilities, a dust mask should be worn when handling small quantities of material. For 
larger quantities, a dust respirator is recommended. 
 
E.MAGNESIUM STEARATE 
 
Synonyms: 
 Magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic acid, 
magnesium salt. 
 
 Structural Formula: [CH3 (CH2)16COO] 2Mg 
 
 Official Status: BP: Magnesium Stearate 
                                 JP: Magnesium Stearate 
                                 PhEur: Magnesium Stearate 
                                 USP-NF: Magnesium Stearate 
 
 Description: 
 Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odour of stearic acid and a characteristic 
taste. The powder is greasy to the touch and readily adheres to the skin. 
 
 Functional Category: 
Tablet and capsule lubricant 
 
Solubility: 
 Practically insoluble in ethanol, ethanol (95%), ether and water; slightly soluble in 
warm benzene and warm ethanol (95%) 
 
Handling  Precautions: 
 Observe normal precautions appropriate to the circumstances and quantity of material 
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 handled. Eye protection and gloves are recommended. Excessive inhalation of 
magnesium  stearate dust may cause upper respiratory tract discomfort, coughing, and 
choking. Magnesium  stearate should be handled in a well‐ventilated environment; a 
respirator is recommended. 
 
 Storage: 
 Magnesium stearate is stable and should be stored in a well closed container in a 
cool, dry place. 
 
F.CARBOXY METHYL CELLULOSE SODIUM 
 
Nonproprietary Names: BP: Carmellose sodium 
                              JP: Carmellose 
                              PhEur: Carmellosum natricum 
                                          USP: Carboxymethylcellulose sodium 
 
 Synonyms: 
Akucell; Aquasorb; Blanose; cellulose gum; CMC sodium; E466; Finnfix; Nymcel; 
SCMC;sodium carboxymethylcellulose; sodium cellulose glycolate; sodium CMC; 
Tylose CB. 
 
 Functional Category: 
 
Coating agent; stabilizing agent; suspending agent; tablet and capsule disintegrant; 
tabletbinder; viscosity-increasing agent; water-absorbing agent. 
 
 Description: 
Carboxymethylcellulose sodium occurs as a white to almost white, odorless, granular 
Powder. 
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 Structural Formula: 
 
 
 
 
Stability and Storage Conditions: 
 
Carboxymethylcellulose sodium is a stable, though hygroscopic material.Aqueous 
solutions are stable at pH 2–10; precipitation can occur below pH 2, and 
solutionviscosity decreases rapidly above pH 10. Generally, solutions exhibit 
maximum viscosity and stability at pH 7–9. 
The bulk material should be stored in a well-closed container in a cool, dry place. 
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5. AIM & OBJECTIVE of work 
AIM: 
         The aim of the work is to design and develop Extended Release tablets of an 
anticonvulsant drug and to carry out the in- vitro release study of the drug. 
 
OBJECTIVES: 
 To carryout preformulation and physicochemical characterization of drug and 
excipients. 
 To formulate extended release tablets of anticonvulsant drug. 
 To optimize the ER formulations based on pre and post compression characterization. 
 To carry out stability studies as per ICH guidelines. 
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6. PLAN OF WORK 
 Fourier Transform Infrared Spectroscopy (FTIR): To study the possible chemical 
interaction between the Excipient and drug. 
 Preparation of extended release tablets of anti-convulsant drug containing matrix 
releasing polymer by Wet Granulation method. 
 Evaluation of blend  
 Angle of repose 
 Bulk density and tapped density 
 Compressibility index 
 Hausner’s Ratio 
 Evaluation of tablets 
 Weight variation 
 Hardness 
 Friability 
 Thickness 
 Content Uniformity 
 Kinetic modeling 
 Evaluation of in vitro release characteristics using USP dissolution apparatus 2 
(paddle). 
 Intermediate and accelerated stability studies of optimized formulation as per ICH 
guidelines to be performed. 
. 
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7. MATERIALS AND METHODOLOGY 
 
 
Sr. 
no. 
 
 
Materials 
used 
 
 
Grade 
 
 
Manufacturer 
 
1 API IP Sun Pharma 
2 HYPROMELLOSE K4M USP/NF Colorcon 
3 
HYPROMELLOSE 
K15M 
USP/NF Colorcon 
4 
CARBOXY METHYL 
CELLULOSE  SODIUM 
IP FMC 
5 
LACTOSE 
MONOHYDRATE 
USP DMV Fonterra 
6 POVIDONE USP BASF Ltd 
7 
COLLOIDAL SILICON 
DIOXIDE 
USP Evonik 
8 
MAGNESIUM 
STEARATE 
USP Amishi drugs and chemicals 
9 INSTACOAT YELLOW USP Colorcon 
Table 1: List of chemicals used with grade and supplier 
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Table 2:List of ingredients with their functional category 
 
Sr. no Instrument Manufacturer 
1 Analytical Balance Sartorius BT224S 
2 Top Loading Balance Sartorius CPA8201 
3 Tapped Density Tester Electrolab ETD-1020 
4 Vibrator Sifter Gansons engg.pvt.ltd 
GMP-LAB Sr no. 236 
5 Octagonal blender Ganson engg.pvt.ltd. GMP ,STD 
6 TabletCompression machine 
16 station 
CADMACH, Ahemdhabad. 
7 Digital Vernier caliper Mituyutoyo 
8 IRMoisture analyser/Balance 
(LOD) 
Sartorius MA150 
9 Tablet hardness tester 8M Dr.Schleuniger pharmatron 8M 
10 Friabilator USP Electrolab EF-2 
S.NO EXCIPIENTS FUNCTIONAL 
CATEGORY 
1 Drug Active  Ingredient 
2 HPMC K15M/K4M Matrix forming Polymer 
3 Lactose monohydrate Diluent 
4 Povidone Binder 
5 Colloidal silicon dioxide Glidant 
6 Magnesium Stearate Lubricant 
7 Purified Water Solvent for granulation 
METHODOLOGY 
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11 High Performance Liquid 
Chromatography 
SHIMADZU LC 2010 C HT 
12 Dissolution Test apparatus LABINDIA DISSO  8000 
13 Fourier Transform Infrared 
Spectrophotometer (FT-IR) 
SHIMADZU,IR PRESTIGE-21 
14 Ultravoilet-visible  
Spectrophotometer 
SHIMADZU UV-1700 Pharmaspec. 
 
15 Rapid Mixer Granulator Sainath Boilers 
Table 3: List of equipments used 
DRUG EXCIPIENT COMPATIBILITY STUDY 
API and excipients were thoroughly mixed in predetermined ratio as per in the given table and 
passed through the sieve No.40. The blend was filled in 10 ml glass vials and closed with gray 
rubber stoppers and sealed with aluminum seal and charged in to stress condition at 
25ºC/60%RH. Similarly API was also kept at above conditions as like the samples. The samples 
were observed for any physical change in 15th and 30th days. 
SERIAL NO. COMPOSITION DETAILS RATIO 
1 Only API 1 
2 API+HPMCK4M Premium 1:1 
3 API+HPMCK15M premium 1:0.5 
4 API+CMC sodium 1:1 
5 API+povidone 1:0.5 
6 API+colloidal silicon dioxide 1:0.1 
7 API+magnesium stearate 1:0.25 
8 API+lactose monohydrate 1:5 
 
Table 4: Composition of API with different excipients used for compatibility study 
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FORMULATION DESIGN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INGREDIENTS QUANTITY USED IN THE FORMULATION 
(mg per tablet) 
  
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
API 
150 150 150 150 150 150 
HPMCK15M - -  50 35 35 
HPMCK4M 30 35 37.5  - - 
CMC Sodium 
15 10 10 - - - 
Lactose 
monohydrate 
81.048 81.049 78.545 76.049 91.5 91.5 
Povidone(PVPK30) 5 5 5 5 5 5 
Colloidal Silicon 
dioxide 
1 1 1 1 1 1 
HPMCK15M 
HPMCK4M 
- 
15 
- 
15 
- 
15 
15 
- 
15 
- 
15 
- 
Magnesium 
stearate 
2.5 2.5 2.5 2.5 2.5 2.5 
Purified Water Q.S Q.S Q.S Q.S Q.S Q.S 
Total weight 300 300 300 300 300 300 
Table 5: Formula for extended release tablets 
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MANUFACTURING PROCEDURE 
STEP I: DISPENSING OF MATERIALS 
All the raw materials are dispensed, packed in an individual clean poly bags and labeled. 
STEP II: SIFTING 
API, HPMC(K4orK15M) and lactose monohydrate sifted through #40 mesh. 
STEP III: PREPARATION OF BINDER SOLUTION 
Povidone was diluted in sufficient quantity of water. 
STEP IV: DRY MIXING: 
Materials were loaded in RMG and are mixed for about 15 minutes at slow speed. 
   STEP V: GRANULATION 
 
   Binder solution is added to the dry mix at slow speed. After the addition of the 
   binder, it is mixed for about three minutes at fast speed to form granules. 
 
   STEP VI: DRYING 
Load blend in rapid dryer at a temperature of 60
0 
and air flow about 40. Drying is continued 
until loss on drying reaches NMT 2%. 
STEP VII: SIZING 
Milled in a multimill using 1.5mm screen. Blend was sifted through 20#mesh. 
STEP VIII: PRE LUBRICATION 
Aerosil, HPMC(K4orK15M) was sifted through 40#mesh and kept aside. Load this in 
octagonal blender along with the blend. 
STEP IX: LUBRICATION 
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Magnesium stearate was sifted through 60#mesh and added to the above step and mixed for 2 
minutes in blender. 
STEP X: COMPRESSION 
   Compression was carried out in 8stn. Physical parameters like Weight variation, Hardness,                        
Thickness, are monitored to meet the predefined specifications and noted. 
 
Punch dimensions (diameter) 9.5mm 
Punch shape Standard concave plain 
 
   STEP XI: COATING 
   25grams of instacoat yellow in 250ml of water kept under mechanical stirring for about                   
20minutes.Coating is done with temperature of 70
o
c with pump rpm of 0-1. Coating is done 
under F4-F6 trials. 
PRECOMPRESSION PARAMETERS 
Determination of bulk density and tapped density 
A quantity of 5g of the powder (W) from each formula was introduced into a 25 ml measuring 
cylinder. After the initial volume was observed, the cylinder was allowed to fall under its own 
weight onto a hard surface from the height of 2.5cm at 2 sec intervals. The tapping was 
continued until to further change in volume was noted. The bulk density and tapped density 
were calculated using the following formulas. 
Bulk density=W/V0 
Tapped density=W/Vt 
Where,   W=weight of the powder, 
V0 =initial volume, 
Vt = tapped volume 
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Hausner’s ratio 
Hausner’s ratio provides an indication of the flow properties of the powder, which could 
result from vibration of the feed hopper. A lower value of indicates better flow and vice 
versa. 
 
 
HAUSNER  RATIO TYPE  OF  FLOW 
Less than 1.25 Good  Flow  (20% Carr’s index) 
1.25 – 1.5 Moderate  (33% Carr’s index) 
(adding glidant normally improves flow) 
Greater than 1.5 Poor  Flow 
(Glidant has marginal effect) 
Table 6: Specifications of Hausner’s ratio 
 
Carr’s Compressibility Index 
Compressibility is the ability of powder to decrease in volume under pressure. 
Compressibility is a measure that is obtained from density determinations. It is also one of 
the simple methods to evaluate flow property of powder by comparing the bulk density and 
tapped density. High density powders tend to possess free flowing properties. A useful 
empirical guide is given by the Carr’s index or compressibility index calculated from bulk 
density and tapped density.  
Carr’s index= (Tapped density- Bulk density/ Tapped density) ×100 
        Hausner’s ratio = Tapped density /Bulk density 
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%  COMPRESSIBILITY FLOW  DESCRIPTION 
<10 Excellent 
11-15 Good 
16-20 Fair 
21-25 Passable 
26-31 Poor 
32-37 Very poor 
>38 Extremely poor 
Table 7: Relationship between %compressibility and flow description 
 
 ANGLE OF REPOSE 
The frictional force in a loose powder can be measured by the angle of repose. Angle of 
Repose () is the maximum angle between the surface of a pile of powder and horizontal 
plane. It is usually determined by Fixed Funnel Method and is the measure of the flow ability 
of powder/granules. A funnel with 10 mm inner diameter of stem was fixed at a height of 2 
cm. over the platform. About 10 gm of sample was slowly passed along the wall of the 
funnel till the tip of the pile formed and touches the steam of the funnel. A rough circle was 
drawn around the pile base and the radius of the powder cone was measured. 
Angle of repose was calculated from the average radius using the following formula. 
 
Where,                      
  = Angle of repose 
h = Height of the pile 
 = tan1 (h/r) = tan1 (height of pile/0.5base) 
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r = Average radius of the powder cone 
ANGLE  OF  REPOSE TYPE  OF  FLOW 
< 25 Excellent 
25 – 30 Good 
30 – 40 Passable 
> 40 Very  Poor 
Table 8: Specifications of angle of repose 
 
POST COMPRESSION EVALUATION PARAMETERS FOR FORMULATED 
TABLETS 
General Appearance 
The general appearance of a tablet, its identity and general elegance is essential for consumer 
acceptance, for control of lot-to-lot uniformity and tablet-to-tablet uniformity. The control of 
general appearance involves the measurement of size, shape, color, presence or absence of 
odour, taste etc. 
Size and Shape 
It can be dimensionally described & controlled. The thickness of a tablet is only a variable. 
Tablets thickness can be measured by Digital Vernier calipers. Tablet thickness should be 
controlled within a 7.5% variation of standard value. 
Hardness 
Tablet requires a certain amount of strength or hardness and resistance to friability to withstand 
mechanical shake of handling in manufacture, packing and shipping. Hardness  generally 
measures the tablets crushing strength. The hardness of all the formulations was checked using 
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Dr.Schleuniger pharmatron 8M hardness tester. The average hardness of 10 tablets of all the 
batches were measured and reported. 
Friability 
Friability of a tablet can determine in laboratory by Electro lab EF2 Friabilitor. This consist of 
a plastic chamber that revolves at 25 rpm, dropping the tablets of weight not less than 6.5 g, 
through a distance of six inches in the Friabilator, which is then operate for 100 revolutions. 
The tablets are reweighed. Compressed tablets that less than 0.1 to 0.5% of the tablet weight 
are considered acceptable. The percentage friability was measured using the formula 
 
 
Where, %F =friability in percentage 
W0 = Initial weight of tablet 
W = Weight of tablets after revolution. 
Weight variation 
Take 20 tablets and weigh individually. Calculate average weight and compare the individual 
tablet weight to the average. The tablet pass the B.P. test if no more than 2 tablets are outside 
the percentage limit and if no tablets differs by more than 2 times the percentage limit. 
Average weight of tablet (mg) Maximum% difference allowed 
80 mg or less 10 
80 mg to 250 mg 7.5 
More than 250 mg 5 
Table 9: Weight variation limit as per BP 
UNIFORMITY OF DRUG CONTENT:The drug content was performed to check the dose 
uniformity in the formulation. Randomly ten tablets were weighed and powdered. As following 
of assay procedure after suitable dilutions, the drug content was determined by HPLC at 215nm. 
%F = {1-(W/W0)} × 100 
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Particulars API 
Column C18 250 mm × 4.6 mm 5µ(Thermohypersil BDS) 
 
Flow rate 2.0 ml/min. 
Detector UV/PDA detector 
Wavelength 215nm 
Injection volume 20µl 
Column temperature 25°C 
Run time 10 minutes 
Elution Isocratic 
Buffer Dissolve 6.8g of potassium dihydrogen phosphate in 1000 ml 
milli-Q water,dissolve and mix well and filter through 0.45µ 
nylon membrane disc filter. 
Mobile phase Mix buffer, acetonitrile, methanol and triethylamine in the ratio 
of 660:140:200:1(v/v) and adjust the pH to 6.0 with dilute 
orthophosphoric acid sonicate to degas. 
Diluent Use mobile phase 
Standard Weigh accurately about 25.0mg of API working standard into 
50ml volumetric flask, add about 30ml of methanol, sonicate for 
15minutes to dissolve with intermittent shaking and dilute to 
50ml with methanol, and mix well. Pipette and dilute 5ml of 
resulting solution into 25ml volumetric flask, and dilute to 25ml 
with diluent and mix well. Centrifuge a portion of this solution at 
3000rpm for 10minutes and use this as standard solution. 
Sample Weigh and powder 20 tablets. Accurately weigh and transfer 
tablet powder equivalent to 50mg of API into a 100ml volumetric 
flask, add about 70ml of methanol, sonicate for about 30 minutes 
to dissolve the contents and dilute to 100ml with methanol and 
mix well. Centrifuge a portion of this solution at 3000rpm for 
10minutes. Pipette and dilute 5ml of resulting into 25ml 
volumetric flask, and dilute to 25ml with diluents. 
Table 10:Chromatographic conditions for assay 
 
 
 
 
 
 
 
 
ASSAY 
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Procedure for API: 
Equilibrate the column with the mobile phase until a baseline is obtained. Inject the sample and 
standard solutions. Record the chromatogram and measure the peak area response of both 
standard and sample preparations of the API. 
Calculation for percentage of API: 
 
            AT        WS       5          100      P         25         AW       P 
% assay of API=       ------- x ------- x ----- x ------- x ----- x ------- x   ------- x ------ x 100 
          AS         50       25         WT      100      5            LC       100 
 
Where, 
AS = area obtained in test sample. 
AT and = average area of standard sample. 
WS = weight of working test sample taken in milligrams. 
LC = Labeled amount of API in mg/ tablet. 
P = % potency of the API working standard on as in basis. 
AW = Average weight of tablet 
WT=weight of powdered tablet taken in mg for sample preparation. 
 
In-Vitro DISSOLUTION STUDY 
Particulars API 
Column C18 250 mm × 4.6 mm 5µ(Thermo Hypersil BDS is suitable) 
 
 
 
 
 
 
 
 
Flow rate 2.0 ml/min. 
Detector UV/PDA detector 
Wavelength 215 nm 
Injection volume 20µl 
Column temperature 25°C 
Run time 10 minutes 
Elution Isocratic 
Mobile phase 660:140:200:1 ratio of buffer, acetonitrile,methanol and 
triethylamine 
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Dissolution parameters API 
Medium 1% w/v Solution of SLS 
Apparatus USP apparatus Type II 
Volume 900 ml 
Agitation 50 rpm 
Measuring time 30minutes 
Temperature 37°C±0.5°C 
Volume withdrawn 10ml 
 
Table 12: Dissolution conditions for API 
 
Diluent Mobile phase 
Table 11: Chromatographic Conditions for the dissolution study of API 
 
 
 
 
 
 
 
 
STANDARD PREPARATION FOR API 
Weigh accurately about 25.0mg of API working standard into 50ml volumetric flask, add about 
30ml of methanol, sonicate for 15minutes to dissolve with intermittent shaking and dilute to 
50ml with methanol, and mix well. Pipette and dilute 5ml of resulting solution into 25ml 
volumetric flask, and dilute to 25ml with diluent and mix well. Centrifuge a portion of this 
solution at 3000rpm for 10minutes and use this as standard solution. 
SAMPLE PREPARATION FOR API 
Weigh and powder 20 tablets. Accurately weigh and transfer tablet powder equivalent to 50mg 
of API into a 100ml volumetric flask, add about 70ml of methanol, sonicate for about 30 minutes 
to dissolve the contents and dilute to 100ml with methanol and mix well. Centrifuge a portion of 
this solution at 3000rpm for 10minutes. Pipette and dilute 5ml of resulting into 25ml volumetric 
flask, and dilute to 25ml with diluents. 
PROCEDURE 
Equillibrate the column with mobile phase for sufficient time until stable baseline is obtained. 
Inject blank, standard and sample preparation into the chromatographic system. Record the 
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chromatogram and measure the peak area response for API. Inject the standard solution as 
bracketing after every 6 injections of sample solution. 
SYSTEM SUITABILITY PARAMETERS 
1. In the chromatograms obtained with the standard preparation, %RSD for 5 replicate 
injections of API peak shall be not more than 2.0. 
2. In the chromatograms obtained with the standard preparation, USP theoretical plates 
obtained for API peak shall be not less than 2000. 
3. In the chromatograms obtained with the standard preparation, USP tiling factor obtained 
for API peak shall be not more than 2.0. 
Procedure: 
 Equilibrate the system with the mobile phase for sufficient time until stable baseline is 
observed. Inject dissolution medium as blank, standard preparation, sample preparation. 
Inject standard preparation as bracketing after six injections of sample preparation. 
 
Table 13:Specifications for Drug release 
Drug Specification 
API 
After 2nd hour, not more than 30% 
After 6th hour 30% to 60% 
12th hour Not less than 85% 
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DATA ANALYSIS
 
The data obtained from the dissolution study were subjected for analysis to know the 
release pattern of the drug from the dosage form. 
To analyze the mechanism of release and release rate kinetics of the dosage form, the 
data obtained were fitted into Zero order, First order kinetic, Higuchi model kinetic and 
Korsmeyer-Peppas model. Based on the r-value, the best-fit model was selected. 
Zero Order Kinetics: 
It describes the system in which the drug release rate in independent of its concentration. 
Qt = Qo + Ko t 
Where, 
Qt = amount of drug dissolved in time t. 
Qo = initial amount of the drug in the solution and 
Ko = zero order release constant. 
If the zero order drug release kinetic is obeyed, then a plot of % drug release versus time 
will give a straight line with a slope of Ko and intercept at zero. 
FIRST ORDER KINETICS: 
It describes the release from the systems in which the release rate is concentration 
dependent. 
log Qt = log Qo + kt /2.303 
Where, 
Qt = amount of drug released in time t. 
Qo = initial amount of drug in the solution. 
Kt = is the first order release constant. 
If the first order drug release kinetic is obeyed, then a plot of log % drug remaining to be 
released versus time will be straight line with a slope of kt / 2.303 and an intercept at t=0 of log 
Qo. 
HIGUCHI MODEL: 
It describes the fraction of drug release from a matrix is proportional to square root of time. 
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Mt / M∞ = kHt1/2 
Where, 
Mt and M∞ = cumulative amount of drug release at time t and infinite time. 
kH = Higuchi dissolution constant reflection formulation characteristics. 
‘F’ is the amount of drug release, ‘K’ is the release rate constant, and‘t’ is the release time. 
If the Higuchi Model of drug release is obeyed, then a plot of cumulative % drug release versus 
t
1/2 
will be straight line with slope of kH. 
KORSMEYER - PEPPAS MODEL: 
The power law describes the drug release from the polymeric system in which release deviates 
from Fickian diffusion, as expressed in following equation, 
log [Mt / M∞] = log k + n log t 
Where, 
Mt and M∞ = cumulative amounts of drug release at time t and infinite time. 
k = constant incorporating structure and geometrical characteristics of CR device. 
n = diffusion release exponent indicative of mechanism of drug release for drug dissolution. 
A plot of log [Mt / M∞] (log % drug release) versus log time( log t) will be linear with 
slope of n and intercept gives the value of log k. Antilog of log k gives the value of k. 
 
STABILITY STUDIES
 
 
Introduction: 
The ICH Q1A guideline defines the stability data package for a new drug substance or 
drug product that is sufficient for a registration application within the three regions of the EC, 
Japan, and the United States. It does not seek necessarily to cover the testing for registration  in 
or export to other areas of the world. 
 
Method: 
Stability studies were carried out at 30°C ± 2°C/65% RH ± 5% RH for 12 months and at 
40°C ± 2°C/75% RH ± 5% RH for 6 months for the selected formulation. 
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The stability studies were done for formulation 5 (F5). These formulations were selected 
depending upon the in-vitro drug release study of  ER layer. The formulation was charged for 
stability for different stability study. 
 
Formulation 
Stability 
condition 
Testing 
frequency 
Tests 
Selected 
Formulation 
30°C ± 2°C/65% 
RH ± 5% RH 
3rd month 
6thmonth 
9th month 
12th month 
Appearance, 
Physical 
Parameters, Assay, 
Uniformity of 
weights, In vitro 
drug release. 
40°C ± 2°C/75% 
RH ± 5% RH 
1st month 
2ndmonth 
3rd month 
6thmonth 
Table 14: Stability testing Protocol 
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8. RESULTS AND DISCUSSION 
Drug Solubility Studies: 
Quantity of API- 1 Quantity of solvents Inference 
100 mg 
100 mg 
100 mg 
100 mg 
100 mg 
 
100 ml of Triethylamine 
100 ml of methanol 
100ml of chloroform 
100 ml of acetonitrile 
100 ml of acetic acid 
 
Soluble 
Sparingly soluble 
Sparingly soluble 
Soluble 
Soluble 
 
Table 15: Drug solubility studies 
 
Evaluation of Active pharmaceutical ingredients: 
Physical parameters like Angle of repose, Bulk density, Tapped density, Carr’s index and 
Hausner’s index and Solubility of the APIs were determined and were given here in the table 
below. 
Parameters API 
Solubility  Soluble in acetic acid, 
sparingly soluble in 
chloroform and practically 
insoluble in water. 
Angle of repose 25.50 
Bulk density 0.445gm/cm
3 
Tapped density 0.666 gm/cm
3
 
Carr’s index 21.80 
Hausner’s ratio 1.329 
Loss on drying 1.45% 
Assay 99.82% 
Table 16: Results for Pre-formulation analysis of API 
 
The solubility, Loss on drying, Assay of the drugs are found to be within the specifications. 
From the Compressibility index, Angle of repose values of API, it can be concluded that API 
have poor flow and this can be improved by granulation. 
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DETERMINATION OF LAMBDA MAX 
 
 
Fig6: lambda max curve 
FTIR STUDY 
The samples that were charged in 30
0
C/65%RH and 40°C/75% RH stability chambers were 
analysed by IR spectroscopy after 30 days. The graphs of the samples were given below. 
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Fig7: FTIR Study of API+HPMC K4M PREMIUM 
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Fig 8: FTIR study of API + METHOCEL K15M PREMIUM 
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Fig 9: FTIR Study of API+LACTOSE 
 
 
 
 
RESULTS AND DISCUSSION 
 
PGPCOPS & RI, NAMAKKAL Page 57 
 
 
Fig 10: FTIR Study of API+POVIDONE 
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FIG 11:FTIR Study of  API+AEROSIL 
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FIG 12: FTIR Study of API+MAGNESIUM STEARATE 
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Fig 13: FTIR study of API+CMC sodium 
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Particulars Ratio Description 
Parameters 
Remarks 
30
o
C/ 65% RH  40
o
C/ 75% RH 
15 
days 
30 
days 
15 
days 
30 
days 
API - 
Yellow 
Powder 
No 
change 
No 
change 
No 
change 
No 
change 
Compatible 
API: HPMC 
K15M Premium 
1:1 
Off white to 
yellow 
Powder 
No 
change 
No 
change 
No 
change 
No 
change 
Compatible 
API: HPMC 
K4M Premium 
1:1 
Off white 
toYellow 
Powder 
No 
change 
No 
change 
No 
change 
No 
change 
Compatible 
API: Povidone 1:0.5 
Off White to 
yellow 
Powder 
No 
change 
No 
change 
No 
change 
No 
change 
Compatible 
API: Lactose 
monohydrate 
1:5 
Off White to 
Yellow 
Powder 
No  
Chang
e 
No  
change 
No  
change 
No  
change 
Compatible 
API: Aerosil 1:0.1 
Off White to 
yellow  
Powder 
No 
change 
No 
change 
No 
change 
No 
change 
Compatible 
API: 
Magnesium 
stearate 
1:0.1 
Off White to 
yellow 
Powder 
No 
change 
No 
change 
No 
change 
No 
change 
Compatible 
Table 17: Results of Compatibility studies 
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Discussion: Pure drug showed characteristic IR absorption bands at 3334 cm-1 
for the N-H group bending, 1645 cm-1 for the C=O stretching. The 
absorption bands at 1556 cm-1 were denoted for stretching 
vibrations of C=C in aromatic ring. After analyzing the physical mixtures of API 
and excipients by FTIR. It was concluded that that there was no interaction 
between API and excipients. 
 
     
PRECOMPRESSION EVALUATION 
Table 18: Evaluation of micrometrics properties of granules 
 
 
 
Formulation 
Code 
Bulk density 
(gm/cm3) 
Tapped density 
(gm/cm3) 
Hausner’s ratio 
(HR) 
Carr’s index 
(CI) 
Angle of 
repose (θ) 
FT-1 
0.445 0.608 1.366 26.80 
32.06 
FT-2 
0.458 0.673 1.460 31.95 
38.23 
FT-3 
0.605 0.686 1.13 11.80 
45.24 
FT-4 
0.583 0.652 1.111 10.58 
45.06 
FT-5 
0.508 0.595 1.17 14.62 
30.04 
FT-6 
0.542 0.635 1.170 14.640 
32.24 
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EVALUATION OF PHYSICAL PARAMETERS OF TABLET 
 
TRIALS 
PHYSICAL PARAMETERS 
Weight 
variation (mg) 
Hardness 
(N) 
Thickness 
(mm) 
Friability 
(%) 
F1 298 ± 5 120± 10 4.21 ± 0.02 0.197 
F2 297 ± 5  130± 10 4.20 ± 0.02 0.099 
F3 298 ± 5  140± 10 4.20 ± 0.02 0.162 
F4 300 ± 5 140± 10 4.18 ± 0.02 0.97 
F5 300 ± 5  150± 10 4.19 ± 0.02 0.08 
F6 300 ± 5  150± 10 4.19 ± 0.01 0.09 
Table 19: Evaluation of Post-Compression properties of Core Tablet 
 
TRIALS 
PHYSICAL PARAMETERS 
Weight 
variation (mg) 
Hardness 
(N) 
Thickness 
(mm) 
F4 302 ± 5 160± 10 4.22 ± 0.02 
F5 303 ± 5  170± 10 4.23 ± 0.02 
F6 303 ± 5  170± 10 4.23 ± 0.01 
Table 20: Evaluation of Post-Compression properties of Coated Tablets 
 
Discussion: 
 In all formulations, all physical parameters of tablets within the limits only. 
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DRUG CONTENT UNIFORMITY 
 
 
 
 
Table 21: Evaluation of Drug Content of blend 
Discussion:  
In all trials, uniformity of content was within the limits i.e. equal proportion of drug content in 
each tablet. 
ASSAY 
DRUG 
CONTENT 
F1 F2 F3 F4 F5 F6 
API 
 
100.1 99.9 99.9 99.8 100 99.9 
Table 22: Evaluation of drug content of ER tablet 
 
IN-VITRO DISSOLUTION STUDY 
 
DISSOLUTION PROFILE OF F1  
 
PERCENTAGE DRUG RELEASE(F1) 
MEDIUM TIME UNIT  Avg% 
1%w/v 
SLS 
medium 
 1 2 3 4 5 6  
2 22.3 23.4 22.1 13.0 12.5 23.7 20 
6 84.2 82.6 68.2 70.1 70.4 70.6 74 
12 92.5 81.2 66.6 77.2 100.2 74.4 82 
Table 23: Dissolution profile of F1 
Drug Content  
Uniformity F1 F2 F3 F4 F5 F6 
API 101 100 99.6 99 100 99.9 
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Discussion: 
Under F1 trial, methocel K4M (low viscosity grade polymer) 30mg/tablet and CMC sodium 
15mg/tablet was used. At 6
th
 hour, the average drug release was 74% which was not within the 
limit (30-60%). At 12
th
 hour, the average drug release was 82% which was not under the 
specified limits (NLT 85%). So the polymer HPMC K4M concentration was slightly reduced in 
the next trials. 
DISSOLUTION PROFILE OF F2 
 
PERCENTAGE DRUG RELEASE(F2) 
MEDIUM TIME UNIT Avg% 
1%w/v 
SLS 
medium 
 1 2 3 4 5 6  
2 17.1 14.5 17.2 15.3 14.5 12.7 15 
6 59.9 60.1 65.0 65.3 75.2 74.8 66 
12 86.1 90.0 84.8 88.0 85.2 87.3 87 
 
Table 24: Dissolution profile of F2 
 
DISSOLUTION PROFILE OF F3 
PERCENTAGE DRUG RELEASE(F3) 
MEDIUM TIME UNIT Avg% 
1%w/v 
SLS 
medium 
 1 2 3 4 5 6  
2 15.5 19 18.2 14.1 15.0 14.8 16 
6 65.0 70.0 75.0 74.5 75.5 70.0 70 
12 95.0 92.6 94.0 94.1 69.4 67.4 85 
Table 25: Dissolution profile of F3 
Discussion: 
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The average drug release was found to be 66% and 70% respectively in F2 and F3 formula by 
increasing the quantity of HPMC K4M  upto 37.5mg/tablet and CMC sodium concentration was 
reduced from 15mg to 10mg/tablet. So trial F4 was planned by using HPMC of higher viscosity 
HPMC K15M. 
 
DISSOLUTION PROFILE OF F4 
PERCENTAGE DRUG RELEASE(F4) 
MEDIUM TIME UNIT Avg% 
1%w/v 
SLS 
medium 
 1 2 3 4 5 6  
2 14.0 18.1 13.9 15.1 15.0 15.1 15 
6 31.4 30.6 31.9 27.2 29.0 30.1 30 
12 79.6 80.6 75.1 75.6 80.9 77.8 78 
Table 26: Dissolution profile of F4 
 
Discussion: 
Under F4 trial, the polymer was changed i.e HPMC K15M which is of  high viscosity grade was 
chosen and CMC sodium was removed. Methocel K15M polymer concentration was about 
16.66% (50mg/tablet) which retards the release more. At 6
th 
hour, the average drug release was 
30% which is within the lower limit of specification (30-60%). At 12
th
 hour, the average drug 
release was 78% which was not within the limit (NLT 85%). It means that the drug retards more, 
so the polymer methocel K15M concentration was reduced in next trial F5. 
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DISSOLUTION PROFILE OF F5 
PERCENTAGE DRUG RELEASE(F5) 
MEDIUM TIME UNIT Avg% 
1%w/v 
SLS 
medium 
 1 2 3 4 5 6  
2 14.0 18.0 15.1 13.9 12.5 12.4 14 
6 39.6 46.1 46.3 39.6 46.0 47.0 44 
12 101 95.0 90.1 87.5 97.5 81 92 
Table 27: Dissolution profile of F5 
Discussion: 
  F5 formula, the polymer methocel K15M concentration was reduced to 11.66% (35mg/tablet). 
It increased the release at 6
th
 hour to an average of 44% which is within the limit of 30-60%. The 
second hour release was found to be 14% which is within the limit of NMT 30%. At 12
th
 hour 
release was found to be  92% which is above the limit of  NLT 85%. 
Drug release was achieved as per the specifications designed for dissolution testing, so next 
reproducible trial to be planned and to check and confirm the drug release as per formula F5. 
 
DISSOLUTION PROFILE OF F6 
PERCENTAGE DRUG RELEASE(F6) 
MEDIUM TIME UNIT 
Avg% 
 
1%w/v 
SLS 
medium 
 1 2 3 4 5 6  
2 11.2 17.8 9.2 6.4 11.7 15.1 12 
6 38.3 57.8 35.7 29.0 41.1 49.9 42 
12 81.5 101.0 81.7 90.5 86.5 97.9 88 
Table 28: Dissolution profile of F6 
Discussion: 
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The drug release of F6 trial is reproducible as F5 formula. So F5 formula was finalized as final 
prototype formula for the extended release formulation. 
COMPARITIVE INVITRO DISSOLUTION PROFILE FROM  F1-F6 
Table 29: Comparitive invitro dissolution profile from F1-F6 
 
 
Fig 14: Comparitive dissolution profile from F1 to F6 
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% CUMULATIVE DRUG RELEASE SPECIFICATIONS 
Average % drug release for all trials 
 F1 F2 F3 F4 F5 F6  
2hr 20 15 16 15 14 12 NMT 30% 
6hr 74 66 70 30 44 42 30-60% 
12hr 82 87 84 78 92 88 NLT 85% 
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DATA ANALYSIS 
 
Kinetic study: 
Formulation-5 was found to be the desired In-vitro dissolution rate, so this formulation was 
selected for determining the nature of drug release from dosage form. 
 
Time 
(in hours) 
Square root 
of time 
Log Time % CDR 
Log(100 % -
CDR) 
Log 
%CDR 
2 
1.414213562 
1.411 14 1.99492 
1.146128036 
 
6 2.449489743 2.44 
 
44 
1.99280 
 
1.643452676 
12 3.464101615 3.46 92 1.99138 
 
1.963787827 
Table 30: Different Kinetic models 
 
 
Formulation 
Zero-order 
kinetics 
First-order 
kinetics 
Higuchi’s 
kinetics 
Korsmeyer- 
Peppas 
 
 
F5 0.963 1 0.981 0.986  
 Table 31: Regression coefficients from all the Kinetic model graphs 
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KINETIC MODELS 
 
 
Fig 15: Zero order kinetics 
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Fig16:First order kinetics 
 
 
Fig 17: Higuchi model 
 
Fig 18:Peppas model 
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Discussion: 
The curve fitting results of the release rate profile of the designed 
formulations gave an idea on the mechanism of drug release. 
Based on the data analysis, it was found that the drug release follows First 
order release kinetics, as it showed the highest linearity and concluded that the 
release mechanism was matrix diffusion controlled. 
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9. SUMMARY 
 
 In the study, anticonvulsant drug was selected for designing extended release matrix tablets.  
Pre-formulation studies were done with API. Compatibility was done before choosing the 
excipients for the study with physical observation and FTIR studies. The samples were 
charged in stability chambers at conditions 30°C/65%RH and 40°C/75%RH for 30 days. All 
the pre-formulation studies and compatibility studies were found to be satisfactory. So 
formulation trials were followed with the selected excipients. 
            Blend for ER formulation was prepared by wet granulation method. Hypromellose 
K4M and Hypromellose K15M were used as release retarding polymers for optimizing the 
formula. 
          Six trials were taken to optimize the release of API in ER form to be within 
specifications. F5 is the optimized formula with 11.66% concentration of HPMC K15M 
polymer which optimized the drug release profile as per predetermined specificatons. A 
reproducibility trial F6 was performed to check the reproducibility of process of drug release 
as per F5. 
           For the ER form, Other excipients include povidone as binder, Lactose monohydrate 
as diluent, colloidal silicon dioxide as glidant and Magnesium stearate as Lubricant. Instacoat 
yellow was used as ready mix.  
          Post-Compression analysis of all formulations like Hardness, Weight variation, 
Friability and Assay were within the limits for all the formulations. In-vitro dissolution 
studies were performed by HPLC method revealed that the formulation F5 released the drug 
as per the specifications. Kinetic Model fitting was done by plotting graphs for Zero-Order 
kinetics, First-Order kinetics, Higuchi’s Kinetic model and Korsemeyer - Peppas kinetic 
model. The formulation selected was F5 which has shown the release rate of the drug by First 
order kinetics and follows matrix diffusion controlled mechanism. Accelerated stability 
studies are being performed. 
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10. CONCLUSION 
          The aim of the study is to design and develop extended release matrix tablets of 
anticonvulsant drugs. Hypromellose, water swellable polymer was selected for the extended 
release of API. 
          The formulation was optimized to obtain the release of API for a sustained period of 12 
hours. In the initial trials, Hypromellose K4M of low viscosity grade was used, then 
Hypromellose K15M of high viscosity grade was selected to check the feasibility of the 
polymer to sustain the release of API. With HPMC K4M  the drug release was not controlled 
to the desired limit of 30-60% at 6
th
 hour. So, a still high viscous polymer Hypromellose 
K15M was used in the formulations F-4 to F-6. The incorporation of the Polymer intra-
granularly at concentration 11.66% gave an optimum release profile within specifications.  
           From graphs plotted for various Kinetic models, it can be concluded that the F5 
follows First-order kinetics as the plots of that model had shown higher regression value. F5 
formula extended the release and follows matrix diffusion controlled mechanism. 
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